ArticlesSecondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
References (32)
- et al.
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study
Lancet
(1989) - et al.
Canadian Atrial Fibrillation Anticoagulation (CAFA) Study
J Am Coll Cardiol
(1991) - et al.
Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile?
Lancet
(1986) - et al.
Atrial fibrillation and anticoagulation: from randomised trials to practice
Lancet
(1993) - et al.
Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study
Neurology
(1978) - et al.
The secondary prevention of stroke in patients with atrial fibrillation
Arch Neurol
(1986) Cardiogenic brain embolism, second report
Arch Neurol
(1989)- et al.
Letter to the editor
N Engl J Med
(1990) Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation study
Stroke
(1990)Stroke Prevention in Atrial Fibrillation. Final results
Circulation
(1991)
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
N Engl J Med
(1990)
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation
N Engl J Med
(1992)
Non-rheumatic atrial fibrillation: warfarin or aspirin for all? Neurological comment
Br Heart J
(1992)
Noninvasive evaluation of the extracranial carotid arteries in patients with cerebrovascular events and atrial fibrillations
Arch Intern Med
(1988)
Cause of cerebral infarction in the carotid territory. Its relation to the size and the location of the infarct and to the underlying vascular lesion
Stroke
(1985)
Cited by (1856)
Focal Anticoagulation by Somatic Gene Transfer: Towards Preventing Cardioembolic Stroke
2023, Heart Lung and CirculationChanging trends and factors influencing anticoagulant use in patients with acute ischemic stroke and NVAF at discharge in the NOACs era
2023, Journal of Stroke and Cerebrovascular DiseasesFactors affecting self-reported bleeding acceptance in acute ischemic stroke survivors on various types of antithrombotic therapy
2023, Journal of Stroke and Cerebrovascular DiseasesCitation Excerpt :Atrial fibrillation (AF), accounting for about 15-20% of all strokes, is associated with 5-fold greater risk of AIS.7 Oral anticoagulation (OAC) with either vitamin K antagonists (VKAs) or non-vitamin K antagonist OACs (NOACs) effectively prevents recurrence of cardioembolic stroke with a relative risk reduction of 60–70%.8 Bleeding represents the most feared adverse event of OAC or antiplatelet therapy (APT).
Holter ECG monitoring for the evaluation of stroke in the internal medicine department
2022, Journal of Stroke and Cerebrovascular DiseasesStrokelore: Therapeutic relevance of lacunar infarcts
2022, Journal of Stroke and Cerebrovascular DiseasesTransient ischemic attack and minor stroke: Diagnosis, risk stratification and management
2022, CMAJ. Canadian Medical Association Journal
- 1
Correspondence to: Dr Peter J Koudstaal, Department of Neurology, University Hospital Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, Netherlands.
Copyright © 1993 Published by Elsevier Ltd.